Previous 10 | Next 10 |
BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells F...
Bank of America launched its coverage on clinical-stage biotech Xenon Pharmaceuticals Inc. ( NASDAQ: XENE ) with a Buy rating on Monday, arguing that the company’s mid-stage epilepsy candidate XEN1101 is poised to become a blockbuster drug. XEN1101 belongs to a clas...
Xenon Pharmaceuticals Inc. (XENE) Q2 2022 Earnings Conference Call August 9, 2022 16:30 ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern ...
Xenon Pharma press release ( NASDAQ: XENE ): Q2 GAAP EPS of -$0.55 misses by $0.06 . Revenue of $0.54M (-75.6% Y/Y) misses by $2.71M . For further details see: Xenon Pharma GAAP EPS of -$0.55 misses by $0.06, revenue of $0.54M misses by $2.71M
Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year Cash runway extended into 2026 following successful completion of equity offering in June Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. ...
BURNABY, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 13th Annual ...
BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, ...
Despite its recent outperformance, the shares of Xenon Pharmaceuticals ( NASDAQ: XENE ) could offer further upside, JP Morgan argued on Thursday, adding the Canadian biotech to the firm’s Analyst Focus List as a Growth Idea. With an Overweight rating, the JP Morgan te...
BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in a fireside chat presentation and one-on-one investor meetings at the William Blair Biotec...
We conclude our roundtable series with Biotech and Healthcare coverage. Seven of our Marketplace contributors give their analysis and share one top idea. Look for more roundtables and analysis this summer from our community of 180+ Marketpalce services. ~ By Tim Murphy, Ma...
News, Short Squeeze, Breakout and More Instantly...
Xenon Pharmaceuticals Inc. Company Name:
XENE Stock Symbol:
NASDAQ Market:
Xenon Pharmaceuticals Inc. Website:
2024-06-25 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 18:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in M...